Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07117539Not ApplicableCompleted

Impact of Different Lung Isolation Devices on Pharyngolaryngeal Injuries After Pulmonary Resection

Role: collaborator

NCT01051076Not ApplicableCompleted

Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)

Role: collaborator

NCT01051544Not ApplicableWithdrawn

Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive

Role: collaborator

All 3 trials loaded